- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02520440
INtestinal Failure, multiPle Organ Failure ANd CItrulline Assessment (IN-PANCIA)
Clinical Evaluation of Gastro Intestinal Failure, Multiple Organ Failure and Levels of Citrulline in Critical Ill Patients
The gastrointestinal dysfunction occurs frequently during the intensive care unit (ICU) stay and is associated with a worse prognosis.
The gastrointestinal failure (GIF) is diagnosed based on symptoms such as bowel distension, ileus, diarrhea, digestive bleeding, or intestinal ischemia. A GIF score based on has been demonstrated to be correlated with outcome, with higher scores indicating higher risk of death. However, GIF may be occult or clinical signs can go undetected in critically ill patients due to the frequent use of analgesic, sedative or neuromuscular blocking agents, acute neurologic diseases, or delirium.
Citrulline is a potential biomarker for small bowel function in critically ill patients with maintained renal function. Normal plasma citrulline levels (12-55 µmol/L) are determined by the balance between gut synthesis and kidney degradation.
GIF is involved in the pathogenesis of multiple organ dysfunctions and failures (MOF) through various mechanisms, and it is often associated with high intra-abdominal pressure (IAP). IAP greater than 12 mmHg, may lead to abdominal compartment syndrome (ACS) and MOF, including cardiac, respiratory and kidney failure. Studies have suggested that GIF can be the consequence rather than the cause of MOF.
The aim of this study is to investigate if plasma citrulline levels is associated with a clinical diagnosis of GIF, and may predict the development of MOF.
Study Overview
Status
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Intensive Care Unit stay of at least 48 hours
Exclusion Criteria:
- Intensive Care Unit stay less than 48 hours
- abdominal trauma or surgery in the last 6 weeks
- inflammatory bowel disease
- a body mass index (BMI) ≥35
- terminal condition.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GIF and/or MOF patients
Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure.
Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
|
Measured plasma amino-acids levels
Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
Measured plasma amino-acids levels
|
Controls
patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay.
Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
|
Measured plasma amino-acids levels
Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
Measured plasma amino-acids levels
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of Gastro Intestinal Failure, defined as the presence of three or more gastro-intestinal symptoms; and Multiple Organ Failure measured by SOFA score
Time Frame: within the first 30 days after admission in intensive care unit
|
to investigate if plasma citrulline levels are associated with a clinical diagnosis of Gastro Intestinal Failure, and may predict the development of Multiple Organ Failure.
Gastrointestinal Failure is defined as the presence of three or more coincident GI symptoms (igh gastric residual volumes (GRV) = maximum GRV above 500 ml at least once.
Absent bowel sounds (BS) = BS not heard on careful auscultation.
Vomiting/Regurgitation= visible vomiting or regurgitation in any amount.
Diarrhoea = loose of liquid stool three or more times per day.
Bowel distension= suspected or radiologically confirmed bowel dilatation in any bowel segment.
GI bleeding= visible appearance of blood in vomit, nasogastric aspirate or stool.).
MOF was defined as the failure of two or more organs or system according to the Sequential Organ Failure Assessment (SOFA)
|
within the first 30 days after admission in intensive care unit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between intra abdominal hypertension (defined as an average of intra-abdominal pressure of the day ≥ 12 mmHg), and development of Gastro Intestinal Failure and Multiple Organ Failure
Time Frame: within the first 30 days after admission in intensive care unit
|
to investigate if increasing of intra abdominal pressure is associated with a clinical diagnosis of Gastro Intestinal Failure, and may predict the development of Multiple Organ Failure.
Intra-abdominal Hypertension (IAH) is defined as an average IAP of the day ≥ 12 mmHg; abdominal compartment syndrome (ACS) is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in IAP above 20 mmHg with new onset organ failure.
|
within the first 30 days after admission in intensive care unit
|
Correlation between levels of Arginine and Glutamine in patients with Gastro Intestinal Failure and Multiple Organ Failure
Time Frame: within the first 30 days after admission in intensive care unit
|
to investigate if plasma Arginine and Glutamine levels are associated with a clinical diagnosis of Gastro Intestinal Failure, and may predict the development of Multiple Organ Failure.
|
within the first 30 days after admission in intensive care unit
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nazzareno Fagoni, MD, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Publications and helpful links
General Publications
- Malbrain ML, Cheatham ML, Kirkpatrick A, Sugrue M, Parr M, De Waele J, Balogh Z, Leppaniemi A, Olvera C, Ivatury R, D'Amours S, Wendon J, Hillman K, Johansson K, Kolkman K, Wilmer A. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med. 2006 Nov;32(11):1722-32. doi: 10.1007/s00134-006-0349-5. Epub 2006 Sep 12.
- Reintam A, Parm P, Kitus R, Starkopf J, Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study. Crit Care. 2008;12(4):R90. doi: 10.1186/cc6958. Epub 2008 Jul 14. Erratum In: Crit Care. 2008;12(6):435.
- Carlson GL, Dark P. Acute intestinal failure. Curr Opin Crit Care. 2010 Aug;16(4):347-52. doi: 10.1097/MCC.0b013e328339fabe.
- Piton G, Manzon C, Cypriani B, Carbonnel F, Capellier G. Acute intestinal failure in critically ill patients: is plasma citrulline the right marker? Intensive Care Med. 2011 Jun;37(6):911-7. doi: 10.1007/s00134-011-2172-x. Epub 2011 Mar 12.
- Puleo F, Arvanitakis M, Van Gossum A, Preiser JC. Gut failure in the ICU. Semin Respir Crit Care Med. 2011 Oct;32(5):626-38. doi: 10.1055/s-0031-1287871. Epub 2011 Oct 11.
- Piton G, Manzon C, Monnet E, Cypriani B, Barbot O, Navellou JC, Carbonnel F, Capellier G. Plasma citrulline kinetics and prognostic value in critically ill patients. Intensive Care Med. 2010 Apr;36(4):702-6. doi: 10.1007/s00134-010-1751-6.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP 1769/2014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Citrulline
-
Texas Tech UniversityAmerican Heart AssociationCompletedAging | Blood Flow | Citrulline
-
Burgos NutritionUniversity of the Basque Country (UPV/EHU); Universidad de León; University of...CompletedAthletes | Citrulline | NitrateSpain
-
University of Arkansas, FayettevilleCompletedDetermine the Effects of Nitrosigine and Citrulline-malate on Flow-mediated Dilation Among Young AdultsUnited States
-
Medical University of GdanskGdansk University of Physical Education and SportNot yet recruitingIron Metabolism Disorders | Inflammatory Response | Exercise Myoglobinuria | Citrulline; Metabolic DisorderPoland
Clinical Trials on Monitoring of plasmatic levels of Citrulline
-
Goethe UniversityUnknownPlatelet Function | Coagulation Disorder, Blood
-
Fox Chase Cancer CenterActive, not recruitingSurgery | Tumors | Primary Neoplasm | Secondary NeoplasmUnited States
-
Asklepion Pharmaceuticals, LLCVanderbilt UniversityCompletedHypertension, Pulmonary | Heart Defects, CongenitalUnited States
-
Asklepion Pharmaceuticals, LLCCompletedAtrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal DefectUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Florida State UniversityCompletedHypertensionUnited States
-
University Hospital, CaenCompletedOther Functional Disturbances Following Cardiac SurgeryFrance
-
Karolinska InstitutetLund UniversityCompletedCovid19 | Bleeding | ThromboembolismSweden
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland
-
Assistance Publique - Hôpitaux de ParisUnknown